KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.

Ashley Nguyen, Diana S-L Chow, Lei Wu, Yang Angela Teng, Mahua Sarkar, Elizabeth G Toups, James S Harrop, Karl M Schmitt, Michele M Johnson, James D Guest, Bizhan Aarabi, Christopher I Shaffrey, Maxwell Boakye, Ralph F Frankowski, Michael G Fehlings, Robert G Grossman

J Clin Pharmacol 61(9) 1232-1242

PMID33908635
PMCIDPMC8457124
DOI10.1002/jcph.1876
发表日期2021-04-28
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Riluzole, a benzothiazole sodium channel blocker that received US Food and Drug Administration approval to attenuate neurodegeneration in amyotrophic lateral sclerosis in 1995, was found to be safe and potentially efficacious in a spinal cord injury (SCI) population, as evident in a phase I clinical trial. The acute and progressive nature of traumatic SCI and the complexity of secondary injury processes can alter the pharmacokinetics of therapeutics. A 1-compartment with first-order elimination population pharmacokinetic model for riluzole incorporating time-dependent clearance and volume of distribution was developed from combined data of the phase 1 and the ongoing phase 2/3 trials. This change in therapeutic exposure may lead to a biased estimate of the exposure-response relationship when evaluating therapeutic effects. With the developed model, a rational, optimal dosing scheme can be designed with time-dependent modification that preserves the required therapeutic exposure of riluzole.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。